Breast MRI is a good tool for supplemental screening in women who have a personal history of breast cancer.
To detect interval cancers in women who have a personal history of breast cancer, breast MRI is an effective tool for supplemental screening.
With findings that add to the growing body of knowledge about the efficacy and utility of breast MRI in detecting cancer, a team of researchers from Seoul National University Hospital determined the scan could do a better job identifying early recurrent breast cancer than mammography in women who have a personal history of the disease. They also found MRI may be more effective in preventing advanced-stage interval cancers.
The team, led by Ga Ram Kim, M.D., from the Seoul National University Hospital, published their findings in Radiology on June 8.
“We aimed to evaluate the performance measures of screening breast MRI in women with a personal history of breast cancer across multiple rounds and to identify sub-groups who might be more at risk for interval cancer,” the team said. “Our results could provide valuable information to establish risk-based surveillance strategies for women with a [personal history.]”
While that body of evidence is mounting about breast MRI’s superior detection capabilities, there is still a lack of research into how well it performs in picking up interval cancers in this particular group of women. Kim’s team set out to assess performance.
For their study, they assessed 6,603 MRI scans conducted on 2,809 Asian women who were, on average, age 47. Based on their analysis, the cancer detection rate was 8.3 cancers per 1,000 screening exams. They also identified a higher interval cancer rate in women with personal histories when compared with women of average risk – 1.5 cancers per 1,000 screenings versus 0-to-0.83 cancers per 1,000 exams.
Overall, they said, breast MRI sensitivity and specificity were 85 percent and 88.3 percent.
Alongside these results, Kim’s team determined interval cancers are associated with three factors:
In addition, the team discovered a three-year median interval between initial cancer surgery and the detection of the second breast cancer. It also took an average of 6.6 months for an interval cancer to be detected after a previous negative MRI, they said. These results indicate that aggressive primary breast cancer, due to rapid growth, can interfere with the identification of second cancers at subsequent screening.
“Tailored surveillance guidelines accounting for the characteristics of primary breast cancer and BPE on MRI scans might be beneficial for women with a personal history of breast cancer,” they said.
It is important to note, though, the team said, that mammography still outperformed breast MRI in detecting interval cancers in women with a personal breast cancer history. Mammography’s detection rate was 3.5-to-3.6 interval cancers per 1,000 screening exams.
Still, even though additional research is still warranted, the team emphasized that because their findings with breast MRI were largely early-stage cancers, using the tool for supplemental screening is preferable to mammography.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.